Shots:
- BI has entered into a global licensing agreement with Immunitas for a preclinical antibody program being developed for chronic inflammatory & autoimmune diseases
- As per the deal, BI will obtain global rights to develop, manufacture, & commercialize the antibody program in exchange for an upfront payment, up to €407.5M (~$479.6M) in development, regulatory, & commercial milestones, plus tiered royalties; further details remain undisclosed
- The licensed Immunitas antibody program is designed to selectively target pathogenic cells at sites of inflammation, with the potential to deliver deeper & more durable therapeutic benefits across multiple inflammatory diseases
Ref: Globenewswire | Image: BI & Immunitas |Press Release
Related News: Boehringer Ingelheim Inks $500M+ Deal with Sitryx Therapeutics for Novel Oral Immune Disease Therapies
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
